Report : Asia Pacific Oscillating Positive Expiratory Pressure (OPEP) Devices Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product (Mouthpiece PEP Devices, Face Mask PEP Devices, and Bottle PEP Devices), Indication [Chronic Obstructive Pulmonary Disease (COPD), Asthma, Bronchitis, Bronchiectasis, Cystic Fibrosis, and Others], and Distribution Channel (Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies)
Hospital Pharmacies Segment to Dominate the Asia Pacific Oscillating Positive Expiratory Pressure (OPEP) Devices Market During 2021–2028
According to a new market research study on “Asia Pacific Oscillating Positive Expiratory Pressure (OPEP) Devices Market to 2028 – COVID-19 Impact and Regional Analysis and Forecast by Product, Indication, and Distribution Channel” the market is expected to reach US$ 25.28 million by 2028 from US$ 16.07 million in 2021. The market is estimated to grow at a CAGR of 6.7% from 2021 to 2028. The report provides trends prevailing in the Asia Pacific oscillating positive expiratory pressure (OPEP) devices market along with the drivers and restraints pertaining to the market growth. Accelerating technological advancements, burgeoning demand for non-pharmacological treatment methods for increasing mobilization, and increasing funding for research and development activities are the major factor driving the growth of the Asia Pacific oscillating positive expiratory pressure (OPEP) devices market. However, meagre awareness and limited access to OPEP devices hinders the growth of Asia Pacific oscillating positive expiratory pressure (OPEP) devices market.
The Asia Pacific oscillating positive expiratory pressure (OPEP) devices market is segmented on the basis of product, indication, distribution channel, and country. Based on product, the market is segmented into mouthpiece PEP devices, face mask PEP devices, and bottle PEP devices. In 2021, the mouthpiece PEP devices segment accounted for the largest market share; and it is likely to register the highest CAGR during the forecast period. Based on indication, the market is categorized into chronic obstructive pulmonary disease (COPD), asthma, bronchitis, bronchiectasis, cystic fibrosis, and others. In 2021, the chronic obstructive pulmonary disease (COPD) segment accounted for the largest share of the market; however, the asthma segment is likely to register the highest CAGR during the forecast period. Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. In 2021, the hospital pharmacies segment held the largest market share; however, the retail pharmacies segment is expected to register the highest CAGR in the market during the forecast period. Further, based on country, the market is segmented into China, Japan, India, Australia, South Korea, and Rest of APAC. In 2021, China held the largest market share; and India is expected to grow at the fastest CAGR during the forecast period.
Allergan Plc.; PARI GmbH; Smiths Medical; AirPhysio; Mercury Medical; Able Healthcare; and Medica Holdings, LLC are among some of the leading companies in the Asia Pacific oscillating positive expiratory pressure (OPEP) devices market. For instance, Monaghan Medical Corporation (Monaghan), a Trudell Medical Corporation subsidiary, and Captis have signed a three-year agreement, forming a partnership between two industry leaders. The exclusive source agreement recognises the significance of Monaghan's patient outcome evidence and gold standard medical equipment, as well as Captis' aim to improve process efficiency and spend money wisely on healthcare.
Contact Us
Contact Person: Sameer Joshi
Phone: +1- 646- 491- 9876
Email Id: sales@businessmarketinsights.com